This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Share
Stay up to date

Home
Topics
Webinars/Videos
Infographics
Articles
Case Studies
Forum
Faculty
Unblocked
Stay up to date

Lipid Metabolism and Disorders Articles

Articles
ApoB triumphs once more over LDL-C and non-HDL-C in risk prediction: ready for guidelines?
Mortensen MB
Journal:
Eur Heart J

First published: May 31, 2024 DOI: 10.1093/eurheartj/ehae257
View
- Share
Articles
Dyslipidemia management in women of reproductive potential: An expert clinical consensus from the national lipid association
Agarwala A, Dixon DL, Gianos E, et al.
Journal:
J Clin Lipidol

First published: May 30, 2024 DOI: 10.1016/j.jacl.2024.05.005
View
- Share
Articles
Current US prevalence of myocardial injury patterns and clinical outcomes among hospitalised patients with familial hypercholesterolaemia: insight from the National Inpatient Sample-a retrospective cohort study
Kumi D, Narh JT, Odoi SM, et al.
Journal:
BMJ Open

First published: May 28, 2024 DOI: 10.1136/bmjopen-2023-077839
View
- Share
Articles
Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry
Shiyovich A, Berman AN, Besser SA, et al.
Journal:
J Am Heart Assoc

First published: May 18, 2024 DOI: 10.1161/JAHA.123.034493
View
- Share
Articles
Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial
Wright RS, Raal FJ, Koenig W, et al.
Journal:
Cardiovasc Res

First published: May 16, 2024 DOI: 10.1093/cvr/cvae109
View
- Share
Articles
Impact of Lipoprotein(a) Levels on Cardiovascular Risk Estimation
Masson W, Waisman G, Corral P, et al.
Journal:
High Blood Press Cardiovasc Prev

First published: May 13, 2024 DOI: 10.1007/s40292-024-00649-x
View
- Share
Articles
Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research
Kamstrup PR, Neely RDG, Nissen S, et al.
Journal:
Eur J Prev Cardiol

First published: May 11, 2024 DOI: 10.1093/eurjpc/zwae032
View
- Share
Articles
Obicetrapib on Top of Maximally Tolerated Lipid-Modifying Therapies in Participants With or at High Risk for Atherosclerotic Cardiovascular Disease: Rationale and Designs of BROADWAY and BROOKLYN
Nicholls SJ, Nelson AJ, Ditmarsch M, et al.
Journal:
Am Heart J

First published: May 3, 2024 DOI: 10.1016/j.ahj.2024.05.002
View
- Share
Articles
Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention
Sniderman AD, Dufresne L, Pencina KM, et al.
Journal:
Eur Heart J

First published: May 3, 2024 DOI: 10.1093/eurheartj/ehae258
View
- Share
Articles
Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a)
Razavi AC, Richardson LC, Coronado F, et al.
Journal:
Am J Prev Cardiol

First published: April 27, 2024 DOI: 10.1016/j.ajpc.2024.100674
View
- Share
Articles
Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT
Burger PM, Bhatt DL, Dorresteijn JAN, et al.
Journal:
Eur Heart J Cardiovasc Pharmacother

First published: April 27, 2024 DOI: 10.1093/ehjcvp/pvae030
View
- Share
Articles
Subclinical Atherosclerosis to Guide Treatment in Dyslipidemia and Diabetes Mellitus
Mszar R, Katz ME, Grandhi GR, et al.
Journal:
Curr Atheroscler Rep

First published: April 25, 2024 DOI: 10.1007/s11883-024-01202-w
View
- Share

1 2 3 … 22

How would you rate this content?

Privacy Policy
Terms of use
Stay up to date
Cookie Preferences
This Knowledge Hub is supported by Novartis.

Lipid Metabolism and Disorders Articles

Articles

ApoB triumphs once more over LDL-C and non-HDL-C in risk prediction: ready for guidelines?

Mortensen MB

Articles

Dyslipidemia management in women of reproductive potential: An expert clinical consensus from the national lipid association

Agarwala A, Dixon DL, Gianos E, et al.

Articles

Current US prevalence of myocardial injury patterns and clinical outcomes among hospitalised patients with familial hypercholesterolaemia: insight from the National Inpatient Sample-a retrospective cohort study

Kumi D, Narh JT, Odoi SM, et al.

Articles

Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry

Shiyovich A, Berman AN, Besser SA, et al.

Articles

Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial

Wright RS, Raal FJ, Koenig W, et al.

Articles

Impact of Lipoprotein(a) Levels on Cardiovascular Risk Estimation

Masson W, Waisman G, Corral P, et al.

Articles

Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research

Kamstrup PR, Neely RDG, Nissen S, et al.

Articles

Obicetrapib on Top of Maximally Tolerated Lipid-Modifying Therapies in Participants With or at High Risk for Atherosclerotic Cardiovascular Disease: Rationale and Designs of BROADWAY and BROOKLYN

Nicholls SJ, Nelson AJ, Ditmarsch M, et al.

Articles

Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention

Sniderman AD, Dufresne L, Pencina KM, et al.

Articles

Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a)

Razavi AC, Richardson LC, Coronado F, et al.

Articles

Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT

Burger PM, Bhatt DL, Dorresteijn JAN, et al.

Articles

Subclinical Atherosclerosis to Guide Treatment in Dyslipidemia and Diabetes Mellitus

Mszar R, Katz ME, Grandhi GR, et al.

Articles

ApoB triumphs once more over LDL-C and non-HDL-C in risk prediction: ready for guidelines?

Mortensen MB

Share

Articles

Dyslipidemia management in women of reproductive potential: An expert clinical consensus from the national lipid association

Agarwala A, Dixon DL, Gianos E, et al.

Share

Articles

Current US prevalence of myocardial injury patterns and clinical outcomes among hospitalised patients with familial hypercholesterolaemia: insight from the National Inpatient Sample-a retrospective cohort study

Kumi D, Narh JT, Odoi SM, et al.

Share

Articles

Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry

Shiyovich A, Berman AN, Besser SA, et al.

Share

Articles

Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial

Wright RS, Raal FJ, Koenig W, et al.

Share

Articles

Impact of Lipoprotein(a) Levels on Cardiovascular Risk Estimation

Masson W, Waisman G, Corral P, et al.

Share

Articles

Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research

Kamstrup PR, Neely RDG, Nissen S, et al.

Share

Articles

Obicetrapib on Top of Maximally Tolerated Lipid-Modifying Therapies in Participants With or at High Risk for Atherosclerotic Cardiovascular Disease: Rationale and Designs of BROADWAY and BROOKLYN

Nicholls SJ, Nelson AJ, Ditmarsch M, et al.

Share

Articles

Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention

Sniderman AD, Dufresne L, Pencina KM, et al.

Share

Articles

Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a)

Razavi AC, Richardson LC, Coronado F, et al.

Share

Articles

Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT

Burger PM, Bhatt DL, Dorresteijn JAN, et al.

Share

Articles

Subclinical Atherosclerosis to Guide Treatment in Dyslipidemia and Diabetes Mellitus

Mszar R, Katz ME, Grandhi GR, et al.

Share